Northern Trust Corp Corvus Pharmaceuticals, Inc. Transaction History

Northern Trust Corp

$600 Billion
Q3 2024

A detailed history of Northern Trust Corp transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 105,450 shares of CRVS stock, worth $506,160. This represents 0.0% of its overall portfolio holdings.

Number of Shares

105,450

Previous 82,990 27.06%

Holding current value

$506,160

Previous $151,000 268.21%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$1.78 - $5.92 $39,978 - $132,963	22,460 Added 27.06%	105,450 $556,000
Q2 2024 Aug 14, 2024	BUY	$1.36 - $2.29 $24,535 - $41,313	18,041 Added 27.78%	82,990 $151,000
Q1 2024 May 14, 2024	SELL	$1.76 - $2.41 $119 - $163	-68 Reduced 0.1%	64,949 $115,000
Q2 2023 Aug 11, 2023	BUY	$1.0 - $3.86 $3,349 - $12,927	3,349 Added 5.43%	65,017 $148,000
Q4 2022 Feb 13, 2023	BUY	$0.74 - $1.04 $6,987 - $9,819	9,442 Added 18.08%	61,668 $52,000
Q4 2021 Feb 08, 2022	SELL	$2.34 - $5.31 $16,464 - $37,361	-7,036 Reduced 11.87%	52,226 $126,000
Q2 2021 Aug 13, 2021	BUY	$2.46 - $3.14 $52,604 - $67,145	21,384 Added 56.45%	59,262 $158,000
Q1 2021 May 12, 2021	BUY	$2.86 - $4.77 $24,118 - $40,225	8,433 Added 28.64%	37,878 $116,000
Q3 2020 Nov 16, 2020	BUY	$2.6 - $5.37 $6,591 - $13,612	2,535 Added 9.42%	29,445 $118,000
Q4 2019 Feb 14, 2020	SELL	$2.56 - $5.44 $860 - $1,827	-336 Reduced 1.23%	26,910 $146,000
Q3 2019 Nov 13, 2019	SELL	$3.01 - $6.5 $344,557 - $744,061	-114,471 Reduced 80.77%	27,246 $82,000
Q2 2019 Aug 13, 2019	SELL	$3.3 - $4.58 $29,934 - $41,545	-9,071 Reduced 6.02%	141,717 $530,000
Q1 2019 May 13, 2019	SELL	$3.75 - $4.97 $2,077 - $2,753	-554 Reduced 0.37%	150,788 $606,000
Q4 2018 Feb 12, 2019	SELL	$3.29 - $8.94 $658 - $1,788	-200 Reduced 0.13%	151,342 $555,000
Q3 2018 Nov 14, 2018	BUY	$8.58 - $11.4 $14,551 - $19,334	1,696 Added 1.13%	151,542 $1.3 Million
Q2 2018 Aug 14, 2018	BUY	$9.42 - $13.73 $577,219 - $841,319	61,276 Added 69.18%	149,846 $1.65 Million
Q1 2018 May 09, 2018	BUY	$7.48 - $11.53 $7,061 - $10,884	944 Added 1.08%	88,570 $1.02 Million
Q4 2017 Feb 14, 2018	SELL	$9.3 - $16.93 $16,953 - $30,863	-1,823 Reduced 2.04%	87,626 $908,000
Q3 2017 Nov 13, 2017	BUY	$11.3 - $17.23 $1.01 Million - $1.54 Million	89,449	89,449 $1.43 Million

Others Institutions Holding CRVS

# of Institutions

Shares Held

30.4M

Call Options Held

1.06M

Put Options Held

84.3K

View Full List

About Corvus Pharmaceuticals, Inc.

Ticker CRVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,553,500
Market Cap $223M
Description
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...

More about CRVS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Account

Northern Trust Corp Corvus Pharmaceuticals, Inc. Transaction History